Coalesce Research Group invites all pharmaceutical and Medical researchers, professionals, faculties and students the from across the globe to attend “International Conference on Biosimilars and Biologics” during April 20-21, 2020 at Dubai, UAE which includes keynote presentations from highly affiliated personalities, Oral talks, Poster presentations and Exhibitions.
ICBB-2020 focuses upon “The Present Scenario and Future Prospects of Biosimilars & Biologics”. This biologics  meeting focuses on the trends which the biosimilar markets is heading on since its launch till the present date and moving on to the projections in future. It takes into its fold the critical developmental procedures, analyses, regulatory factors and also pharmacovigilance including post marketing surveillance and clinical studies. Innovation and compliance to regulatory guidelines are the most critical aspects towards biosimilars and follow on biologics development and successful launching to the market.

HIGHLIGHTS

Current Challenges in Developing Biosimilars and Biologics, Emerging Biosimilars in Therapeutics, Biosimilars Analytical Strategies, Regulatory Approach for Biosimilars, Globalization of Biosimilars, Biosimilars Role in Oncology and Gastroenterology, Biologics and Biosimilars in inflammatory bowel disease, Biosimilars vs Biologics, Biosimilars vs Generics, Biologics as therapeutics, Immunogenicity of Biosimilars, Intellectual Property Rights, Monoclonal Antibody and Fusion Protein Biosimilars, BCS and IVIVC Based Biowaivers, Biosimilar Companies and Market Analysis, Legal Issues and BPCI ACT, Biosimilars Research Pipeline, Bioequivalence Assessment, Biopharmaceuticals and Biotechnology, Current Trends in Pharmaceutical industry and Biosimilars in Rheumatology and Dermatology

Conference Website: https://coalesceresearchgroup.com/conferences/biosimilars-biologics

Abstract Submission: https://coalesceresearchgroup.com/conferences/biosimilars-biologics/abstractsubmission

Registration: https://coalesceresearchgroup.com/conferences/biosimilars-biologics/registration

WHY ATTEND?

At the moment, the uptake of biosimilars is still limited, especially in the US due to a lack of confidence towards biosimilars by some stakeholders; uncertainty about the interchangeability and substitution of biosimilars; and a hospital financing system that discourages the use of them. This year’s conference gathers biosimilars main players in the industry, representatives of pharmaceutical and biotechnological companies, professionals from governments, physicians and researchers to discuss updates in biosimilars’ development and regulatory restraints around them. Professionals and leaders will join an open conversation about barriers in developing biosimilars, cost of developing biosimilars; additionally, discover the way to introduce biosimilars to the market and provide sufficient knowledge for potential customers and consumers. Attendees will have the opportunity of networking with experts in the field while learning and sharing analytical views of the current biosimilars scene.

KEY PRACTICAL LEARNING POINTS OF THE SUMMIT

• An overview of the current biosimilars market
• Barriers in developing biosimilars
• Cost of developing biosimilars
• A summary of regulatory pathways in various geographic regions
• How biosimilars is developing in different countries
• An overview of approved biosimilars in the E.U., U.S., India, South Korea and Latin America.-
• The market impact of biosimilars on their reference biologics
• The top ten biologics on the focus of biosimilar developers
• Ways to commercialize biosimilars
• Implications of biosimilars in patient treatment

WHO SHOULD ATTEND

CEOs | CIOs|VPs | CTOs| Directors|Department Heads|Technical Analysts|Research Engineers |Specialists| Government officers specializing in:

·         Bioequivalence assessment

·         Biopharmaceuticals

·         Biologics/Biotechnology/ Biogenerics

·         Biosimilars Legal Affairs

·         Drug Pricing and Reimbursement

·         Regulatory Compliance

·         Preclinical and Clinical Development

·         Quality Affairs/ Quality Control

·         Biopharmaceuticals

·         Intellectual property

·         Clinical Immunology

·         New Product Development and Pharmacovigilance

·         Clinical Immunology

·         Immunology

·         Drug Safety

·         Preclinical Development

·         Vaccines Development

·         Validation

·         Analytical Characterization

·         Antibody Discovery

·         Oncology

·         Infection and Immunity

·         Risk Management

·         Clinical Program

·         Personalized Medicine

·         Portfolio Planning

·         Regulatory Affairs

·         Pharmacovigilance

·         Global Strategy and Antibody Engineering

TARGET AUDIENCE

·         Pharmaceutical Companies,

·         Pharma Associations & Societies,

·         Biotechnology Experts/Business Entrepreneurs.

·         R&D, F&D Scientists

·         Intellectual Property Attorneys

·         Ph.D. and Post Doctorate ScholarsRegards

CONTACT US

Jon Peters

Biosimilars and Biologics 2020

T: +1-718-543-9362

biosimilars@coalescemeetings.com